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Abstract
Background: Silibinin has been shown to have anti-HCV activity and immune-modulating properties by regulating
dendritic cell (DC) function. DCs are antigen-presenting cells that, together with regulatory T cells (Treg), play a
pivotal role in controlling alloimmune, as well as anti-HCV immune responses.
Methods: Twelve liver transplant patients with HCV recurrence received iv infusion of Silibinin (iv-SIL) for 14
consecutive days. Using flow cytometry, before and at the end of treatment, we determined the frequencies of
circulating myeloid (m) and plasmacytoid (p) DC and Treg and the expression of costimulatory/coregulatory molecules
by the DC subsets and Treg. Statistical analysis was performed using the paired Student’s t test and Pearson
correlation test.
Results: After iv-SIL treatment, we observed an elevated plasmacytoid dendritic cell (pDC)/myeloid dendritic
cell (mDC) ratio, while pDC displayed lower HLA-DR and higher immunoglobulin-like transcript 4 (ILT4), CD39,
and HLA-G expression compared to the pretreatment baseline. In addition, after iv-SIL, mDC showed increased
inducible costimulator ligand (ICOSL) expression. No changes were detected in Treg frequency or programed
death (PD)-1 expression by these cells. Moreover, several correlations between DC/Treg markers and clinical
parameters were detected.
Conclusions: This descriptive study, in liver transplant patients with HCV recurrence, reveals the impact of iv-SIL on
DC and Treg. The changes observed in circulating pDC and mDC that have previously been associated with
tolerogenic conditions shed new light on how iv-SIL may regulate anti-viral and alloimmunity. We have also
observed multiple clinical correlations that could improve the clinical management of liver transplant patients
and that deserve further analysis.
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Background
Recently, several experimental and clinical studies have
described the anti-oxidative, anti-fibrotic and anti-viral
properties of Silibinin, a flavonolignan representing the
main component (60 %) of silymarin extracted from the
milk thistle (Silybum marianum gaertneri). In vivo and
in vitro studies have shown that the anti-HCV effect of
Silibinin involves stimulation of toll-like receptor (TLR)
7, interferon regulatory factor 3, and p38 mitogen-
activated protein kinase pathways [1]. The safety and
efficacy of Silibinin as anti-viral therapy has been dem-
onstrated in chronic HCV-infected patients and in liver
transplant patients with HCV recurrence unresponsive
to standard combined therapy with interferon/ribavirin
[2].
There is evidence that Silibinin has also immune-
modulating properties and polarizes Th1/Th2 immune
responses through functional modifications of dendritic
cells (DCs) [3]. DCs are innate immune cells that are
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also important in the induction and regulation of adap-
tive immunity. Several subsets of DC have been identi-
fied, principally conventional myeloid (m) DC and also
type-1 interferon (IFN)-producing plasmacytoid (p) DC,
that may be specialized for modifying the quality,
strength, and duration of immune responses [4, 5].
Silibinin has been shown to suppress the expression of
MHC class I and II and costimulatory molecules (CD80,
CD86) by murine bone marrow-derived DC, and this
phenomenon has been associated with impairment of
LPS-induced IL-12 secretion by these cells [3]. More-
over, Silibinin-treated DCs are highly proficient at anti-
gen capture mediated via mannose receptor-mediated
endocytosis and fail to induce Th1 responses and a nor-
mal cell-mediated immunity [3].
The outcome of HCV-related hepatitis depends on the
balance between immune reactivity and immune sup-
pression/tolerance. After viral infection, activated DCs
induce the differentiation of naïve T cells into virus-
specific CD4+ (IFN-γ; anti-viral Ab) and CD8+ T cells
for adaptive immunity. It appears that via TLR7 plasma-
cytoid dendritic cell (pDC) sense HCV-RNA that is
transfered inside the pDC after their contact with in-
fected cells, thus inducing type-I IFN secretion. Despite
these events, with potential to control and eliminate
viral infection, the immune response fails to eliminate
the virus in most HCV infections. During the past few
years, several authors have demonstrated functional im-
pairment of DC in HCV-infected patients. Thus, Natter-
mann et al. [6] have shown decreased numbers of
BDCA1+ (myeloid dendritic cells (mDC)) and BDCA2+
DC (pDC) in peripheral blood of HCV-infected patients,
together with a concomitant increase in their numbers
in liver tissue. The authors suggested that the interaction
of the HCV E2 Ag with CD81, a member of the tetra-
spanin family (considered the cellular receptor for entry
of HCV expressed on DC), could result in impaired mi-
gration of DC towards the chemokine CCL21 that mod-
ulates DC trafficking from sites of infection to lymphoid
tissue, with consequent impairment of T cell priming. In
addition, decreased CD86 expression and IL-12 secre-
tion by DC from chronically HCV-infected patients has
been detected, along with impaired allogeneic T cell
stimulatory activity of mDC and reduced IFN-γ and in-
creased IL-10 secretion by T cells. It has been reported
that the functional impairment of DC in HCV-infected
patients may be related to the presence of HCV-RNA in
both mDC and pDC [7]. By contrast, several observa-
tions show a normal ability of DC from chronically
HCV-infected patients to prime T cells suggesting the
need for improved understanding of the role of DC sub-
sets in HCV pathogenesis [8–10].
Recently, inhibition of effector T cells by regulatory T
cells (Treg) and the PD-1/PD-L1 pathway has been
described as a mechanism responsible for regulating
adaptive T cell responses to HCV [11]. Treg are defined
as a subset of CD4+T lymphocytes that highly express
CD25 (IL-2 receptor α-chain) on their surface and the
transcription factor Foxp3 intracellularly and constitute
approximately 5 % of peripheral CD4+ T lymphocytes.
Treg critically suppress HCV-specific lymphocyte prolif-
eration, differentiation and cytokine production [11] and
promote alloimmune tolerance [12–15].
Regulation of T cell responses, including the induction
of Treg, has been shown to be under the control of im-
mune regulatory molecules expressed by DC subsets, in-
cluding ICOSL (inducible costimulator ligand), PD-L1 (B7
homologue-1 = programmed death ligand-1; CD274),
CD39 (ectonucleoside triphosphate diphosphohydrolase-
1), and the non-classical HLA class I molecule HLA-G
and its receptor, immunoglobulin-like transcript 4 (ILT4)
[12]. However, enumeration of DC subsets and Treg and
the expression of these immune regulatory molecules on
DC subsets and PD-1 on Treg have not been examined in
relation to HCV recurrence and Silibinin treatment after
liver transplantation.
In this study, we examined peripheral blood DC sub-
sets, Treg, and the expression by these cells of immune
regulatory molecules in stable liver transplant patients
with HCV recurrence treated for 14 consecutive days
with iv infusion of Silibinin (iv-SIL). Our findings reveal
changes in circulating pDC and mDC that have previ-
ously been associated with tolerogenic conditions (ele-
vated pDC/mDC ratio, increased expression of ILT4,
CD39, and HLA-G on pDC and increased expression by
mDC of ICOSL) suggesting how iv-SIL might regulate
anti-viral and alloimmunity. We have also observed mul-
tiple clinical correlations that could improve the clinical
management of liver transplant patients and that deserve
further analysis.
Methods
Study population and treatment
Twelve, clinically-stable, adult liver transplant recipients
with normal graft function were eligible for the study
(Table 1) and received iv-SIL (20 mg/kg/day) for 14 con-
secutive days. Eligible patients were males or females
aged ≥18 and ≤70, with a ≥1 year posttransplant follow-
up, positive serum HCV-RNA by PCR, presence of liver
fibrosis as assessed by liver biopsy and/or Fibroscan,
with absence of biochemical, clinical, and/or histological
evidence of rejection. Female patients of child-bearing
age agreed to use a contraceptive method and had a
negative pregnancy test at screening. Exclusion criteria
included active hepatocellular carcinoma or other neo-
plasia (excluding cutaneous carcinoma), active biliary
tract anomalies, a rejection episode in the 6 months pre-
ceding study inclusion, active interferon treatment,
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creatinine clearance <50 ml/min, history of drug, alcohol
or other substance abuse, or other factors limiting their
ability to co-operate during the study.
This study was reviewed and approved by the Ethics
Committee of the Ospedale Policlinico–Università degli
Studi di Bari, Italy, and patients gave their written in-
formed consent to be part of the study.
HCV-RNA level, HCV genotype, and IL-28B polymorphism
HCV-RNA levels and HCV genotype were determined
using the VERSANT® HCV RNA 1.0 Assay (kPCR) and
VERSANT® HCV genotype 2.0 Assay (LIPA), respect-
ively, according to the manufacturer’s instruction
(Siemens, Munich, Germany).
DNA for IL-28B polymorphism assay was extracted by
using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. Real-
time PCR was performed on the ABI Prism 7900HT Se-
quence Detection System (Applied Biosystems, Monza,
Italy). Primers and probes for allelic discrimination for
homozygotic (CC and TT) and heterozygotic (CT) genes
were as follows: Forward 5′GTGCCTGTCGTGTACT-
GAACCA3′, Reverse 5′AGCGCGGAGTGCAATTCA3′,
Probe_C FAM-CCTGGTTCGCGCCTT-MGB, Probe_T
VIC-CCTGGTTCACGCCT-MGB.
Peripheral blood mononuclear cell isolation and
cryopreservation
Peripheral venous blood samples were collected and per-
ipheral blood mononuclear cells (PBMC) isolated, cryo-
preserved, and recovered, as described in detail [16]. We
have shown previously [17] that results obtained staining
cryopreserved PBMC do not differ significantly from
those obtained using freshly-isolated cells.
DC subset analysis
As described previously in detail [16], PBMC were
stained on melting ice with a lineage (lin) fluorochrome-
conjugated monoclonal antibody (mAb) cocktail (anti-
CD3, -CD14, -CD19, -CD20). The cells were also stained
at the same time with the DC subset-specific mAbs
blood DC Ag (BDCA)-1 (CD1; clone AD5-8E7) and
BDCA-2 (CD303; clone AC144) (both from MiltenyiBio-
tec, Auburn, CA), as well as for HLA-G (clone 87G),
CD85d (ILT4; clone 42D1) (both from eBioscience, San
Diego, CA) HLA-DR (clone L243), CD86 (clone IT2.2),
CD83 (clone HB15e), PD-L1 (clone MIH1), CD39 (clone
TU66), and the inducible costimulator ligand (ICOSL;
clone 2D3/B7-H2) (all from BD PharMingen, San Diego,
CA). DC subsets were identified as mDC (lin−BDCA-1
+BDCA-2−) or pDC (lin−BDCA-1−BDCA-2+). DC
phenotype was further characterized by flow cytometric
analysis (FACS-Canto, BD Bioscience), gating on either
the mDC or pDC population. Data were analyzed using
Facs Diva software (BD Bioscience). Due to low cell re-
covery for DC analysis in 2 patients, data from 10 in-
stead of 12 patients were available (demographic,
clinical, and viral load data were not different).
Treg analysis
PBMC were stained with fluorochrome-conjugated
anti-CD4 (RPA-T4), anti-CD25 (M-A251), anti-CD3
(UCHT1), anti-CD127 (hIL; 7R-M21), anti-PD-1
(MIH4), and anti-Foxp3 (259D/C7) mAbs from BD
PharMingen. Intracellular staining for Foxp3 was con-
ducted after surface staining with anti-CD3, -CD4,
-CD127, and -CD25 mAbs, as recommended by the
manufacturer (BD PharMingen). Treg were defined as
CD4+CD127−CD25hiFoxp3+ by flow cytometry, and
the results expressed as percent total CD4+ cells.
Foxp3 expression was also expressed as mean fluores-
cence intensity (MFI).
Statistical analysis
Results are expressed as arithmetic means ± SD and box
and whiskers plots. Statistical analyses were performed
using the paired Student’s t test and Pearson correlation
test. Two-tailed P values <0.05 were considered
significant.
Results
iv-SIL treatment significantly reduces HCV viral load in
liver transplant patients
Twelve liver transplant patients with established HCV
recurrence were treated for 14 days with iv-SIL (20 mg/
kg/day, i.v.). As previously shown in a larger cohort of
patients [2], on day 14 of treatment, HCV viral load
(Fig. 1) decreased significantly compared with the pre-
treatment level (6.38 ± 0.58 vs 4.19 ± 1.25 log10 IU/ml).
Table 1 Demographics of study population
No. patients 12
Age at transplant, yr ± SD (range) 52.88 ± 4.70 (44–60)
Time posttransplant, yr ± SD (range) 7.70 ± 6.31 (1–21)
Age at study, yr ± SD (range) 60.58 ± 7.10 (48–70)
Gender (M:F) 10:2
Immunosuppression at study
Tacrolimus 7/12
Cyclosporine 2/12
mTor inhibitors 3/12
ALT, U/L ± SD 131.4 ± 117.2
AST, U/L ± SD 85.0 ± 52.6
Total bilirubin, mg/dl ± SD 1.79 ± 2.31
HCV genotype (1/2/3; %) 75/8/17
IL28B genotype (CC/CT/TT; %) 25/50/25
HCV-RNA (log 10 IU/ml; mean ± SD) 6.38 ± 0.58
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Sixteen days after the end of treatment, viral load mean
values were similar to baseline (6.14 ± 0.71 log10 IU/ml;
data not shown). The treatment was well-tolerated, with
no changes in immunosuppressant trough levels and
with no dosage adjustments required.
iv-SIL treatment is associated with an elevated pDC/mDC
ratio
Peripheral blood DC subset analysis has been shown to
be helpful in the immunological monitoring of stable
liver transplant patients [12, 17, 18] and those undergo-
ing rejection [19]. In the present study, we analyzed cir-
culating DC subsets by flow cytometric analysis, before
and after iv-SIL, as described in the “Methods” section.
As shown in Fig. 2, the BDCA-2+ pDC frequency was
not modified significantly by 14 consecutive days of iv-
SIL (Fig. 2a) nor was the frequency of Lin−BDCA-1+
mDC at the end of iv-SIL treatment (Fig. 2b). However,
the mDC frequency at the end of the treatment was in-
versely correlated with the serum AST level (Fig. 2c).
Notably, when the pDC/mDC ratio was calculated, a sig-
nificantly higher ratio was detected at the end of treat-
ment (Fig. 2d, 0.58 ± 0.27 vs 0.79 ± 0.31, p < 0.0386), but
no correlation with ALT level, total bilirubin, HCV geno-
type, or IL-28B polymorphism [20] at baseline or at the
end of treatment was observed (data not shown).
iv-SIL modulation of costimulatory and coregulatory
molecule expression by peripheral blood DC subsets
DC function and the outcome of DC-T cell interactions
may depend on the net costimulatory and coregulatory
signals delivered by DC. Thus, we used flow cytometric
analysis to identify and quantify selected immune costi-
mulatory/coregulatory molecules (CD83, CD86, ICOSL,
PD-L1, HLA-G, ILT4, CD39) and HLA class II on
circulating mDC and pDC before and after 14
consecutive days of treatment with iv-SIL. The data
(Tables 2 and 3) show that after iv-SIL exposure, the ex-
pression of costimulatory and coregulatory molecules on
circulating mDC was not modified significantly, except
for higher expression of the coregulatory molecule
ICOSL (Fig. 3a, %: 29.6 ± 12.6 vs 36.2 ± 7.2; p < 0.0122).
By contrast, after iv-SIL, pDC exhibited a modest but sig-
nificant downregulation of HLA-DR expression (Fig. 3b;
MFI: 1673.5 ± 525.4 vs 1523.4 ± 531.1; p < 0.0092) and up-
regulation of the non-classical HLA class I molecule
HLA-G (Fig. 3c; %: 26.2 ± 8.1 vs 36.1 ± 8.6; p < 0.0449) and
its receptor ILT4 (Fig. 3d; MFI: 2303.6 ± 632.8 vs 2743.4 ±
718.6; p < 0.0165). Moreover, pDC from iv-SIL patients ex-
hibited higher expression of the ectonucleosidase CD39
(Fig. 3e: 16.2 ± 8.7 vs 22.1 ± 9.4 %; p < 0.0377; Fig. 3f: MFI:
349.7 ± 116.9 vs 437.8 ± 143.6; p < 0.0456) compared with
cells isolated before iv-SIL treatment. No significant
change in PD-L1/CD86 ratio was found after iv-SIL
(Table 3). Although the magnitude of these differences is
small, these findings suggest that by modulating costimu-
latory and coregulatory molecule expression by peripheral
blood DC subsets, iv-SIL could influence the immune
response.
Correlations between peripheral blood DC subset markers
and clinical parameters
We next analyzed possible correlations between circulat-
ing DC subset markers and clinical parameters (AST,
ALT, total bilirubin, HCV-RNA, HCV genotype, IL-28B
genotype) before (Fig. 4a–c) and after iv-SIL treatment
(Fig. 4d–g). In addition, DC markers at baseline were
also correlated with clinical parameters at the end of iv-
SIL treatment (Fig. 4h–i).
At pretreatment baseline, serum HCV-RNA was in-
versely correlated with CD39 (%) on pDC (Fig. 4a) and
serum ALT was positively correlated with HLA-DR
(MFI) on mDC (Fig. 4b), whereas a positive correlation
between CD86 expression (MFI) on blood pDC with
total bilirubin level was found (Fig. 4c).
At the end of the treatment, there was an inverse cor-
relation between HCV-RNA and ICOSL expression (%)
on mDC (Fig. 4d). Moreover, there was a positive correl-
ation between serum ALT and AST and PD-L1 expres-
sion (% and MFI) and PD-L1/CD86 ratio on mDC
(Fig. 4e, g) and also a positive correlation between HLA-
G expression (MFI) on blood pDC and total bilirubin
level (Fig. 4f ).
Notably, HCV-RNA at the end of treatment was corre-
lated inversely with ICOSL expression on mDC at base-
line (Fig. 4h), and serum ALT was positively correlated
with HLA-DR expression (MFI) on mDC at baseline
(Fig. 4i).
Fig. 1 HCV viral load is reduced significantly in liver transplant patients
treated with iv-SIL (20 mg/kg/day) for 14 consecutive days. The box
and whisker plots show mean and min to max values before (pre) and
after treatment (post)
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At the moment, data provided by this study do not
allow to conclude on the real clinical impact of such cor-
relations. Thus, larger prospective study is needed to val-
idate their clinical significance.
iv-SILtreatment does not significantly influence the Treg
compartment
Treg and the PD-1/PD-L1 pathways have been described
as mechanisms responsible for balancing of HCV adap-
tive T cell responses [11], and therefore, Treg frequency
and PD-1 expression were analyzed by flow cytometry,
before and after 14 days of treatment with iv-SIL. As
shown in Fig. 5a, Treg frequency, Foxp3 expression, and
PD-1 expression were modestly but not significantly in-
creased after iv-SIL treatment. Notably, at the end of
treatment, PD-1 expression on Treg (% and MFI) was
correlated positively with HCV viral load and serum
AST levels (Fig. 5b), whereas no correlation with ALT,
total bilirubin, HCV genotype, or IL-28B polymorphism
was observed either at baseline or at the end of treat-
ment (data not shown).
Discussion
Both DC and Treg are believed to play important roles
in the regulation of alloimune responses, host responses
to HCV infection [21], and transplant outcome [13, 22].
In this study, we have monitored key immunological pa-
rameters previously recognized to be involved in the
regulation of anti-viral immunity and tolerance/rejection
for the first time in liver transplant patients with HCV
recurrence treated for 14 consecutive days with iv-SIL.
Recently, in a single-center, prospective, randomized,
Fig. 2 iv-SIL treatment elevates circulating pDC/mDC ratio. PBMC were analyzed before (pre) and after (post) iv-SIL treatment by flow cytometry,
as described in the “Methods” section. The frequencies of pDC (a Lin−BDCA-2+) and mDC (b Lin−BDCA-1+), correlation between mDC and AST at
the end of treatment (c), and the pDC/mDC ratio (d) are shown
Table 2 Modulation of costimulatory and coregulatory molecule expression by iv-SIL
% (mean ± SD) pDC mDC
Pre Post p Pre Post p
HLA-DR 92.9 ± 5.5 90.9 ± 7.8 0.1600 93.7 ± 9.7 87.5 ± 17.3 0.1035
CD83 45.9 ± 16.2 50.3 ± 20.6 0.6231 26.7 ± 10.7 37.7 ± 23.1 0.1793
CD86 59.8 ± 14.2 65.6 ± 10.9 0.2250 90.6 ± 5.3 87.8 ± 14.0 0.6306
ICOSL 45.1 ± 18.3 52.2 ± 12.3 0.2758 29.6 ± 12.6 36.2 ± 7.2 0.0122
PD-L1 18.9 ± 11.2 25.5 ± 12.0 0.0883 10.6 ± 6.8 17.0 ± 10.6 0.0938
HLA-G 26.2 ± 8.1 36.19 ± 8.6 0.0449 45.8 ± 10.3 50.8 ± 11.6 0.3614
IL-T4 97.3 ± 2.7 96.8 ± 6.1 0.7293 89.3 ± 5.7 91.7 ± 5.6 0.3397
CD39 16.2 ± 8.7 22.1 ± 9.4 0.0377 69.4 ± 7.6 74.0 ± 10.7 0.3064
PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86,
ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (%, mean SD) by mDC and pDC is presented. Italicized values denote significance
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parallel-group, double-blind, placebo-controlled, phase 2
trial, we have shown that Silibinin monotherapy has sig-
nificant anti-viral activity in patients with established
HCV recurrence in the graft and who are unresponsive
to standard therapy. We have also confirmed the safety
and tolerability of iv-SIL without interaction with im-
munosuppressive drugs [2]. In the present study, we
show that, associated with a significant decrease in HCV
viral load, iv-SIL induces changes in circulating DC that
have previously been associated with tolerogenic condi-
tions [12, 23], providing new insight into how iv-SIL
may regulate alloimmunity and anti-HCV immunity in
liver transplant patients. After iv-SIL treatment, we ob-
served a higher pDC/mDC ratio and pDC exhibited re-
duced HLA-DR and elevated ILT4, HLA-G, and CD39
expression compared with baseline values. In addition,
after iv-SIL administration, blood mDC showed higher
ICOSL expression. By contrast, no significant changes
were detected in Treg frequency or PD-1 expression.
Our study also reveals significant correlations between
clinical parameters and DC and Treg markers which
could prove helpful, especially if confirmed in larger,
prospective studies, in the clinical management of liver
transplant patients.
In humans, conventional mDC and “non-conven-
tional” pDC exhibit inherent tolerogenic properties in
the healthy steady-state, and each plays an important
role in regulating innate and adaptative immunity. There
is also evidence that pDC, more than mDC, might be
predisposed to induce tolerance [24–27]. We have
shown that tolerant and prospective weaning liver trans-
plant patients exhibit a significantly higher incidence of
circulating pDC relative to mDC compared with those
patients requiring maintenance immunosuppression
[17]. Moreover, modulation of the pDC/mDC ratio has
been proven to have a biological influence not only in
the transplant setting but also in other diseases or
conditions, such as chronic obstructive pulmonary dis-
ease and pregnancy [28, 29]. The findings of the current
study now show that after 14 consecutive days of iv-SIL,
the pDC/mDC ratio in peripheral blood is higher than
at baseline and it does not correlate with any of clinical
parameters evaluated, including the viral load. These
data therefore suggest that iv-SIL in liver transplant pa-
tients may promote redistribution of peripheral blood
DC subsets in favor of pDC. Whether or not this finding
might be correlated with a regulatory/tolerogenic effect
of iv-SIL will be addressed in further studies. Moreover,
blood mDC after iv-SIL were modestly but not signifi-
cantly reduced; their frequency was inversely correlated
with serum AST level at the end of the treatment.
Since DC function and the outcome of DC-T cell in-
teractions may depend on the net costimulatory and cor-
egulatory signals delivered by the DC, we tested the
expression of several costimulatory and coregulatory
molecules on blood DC subsets. Notably, we found that
the mean fluorescence intensity of HLA-II DR on pDC
was slightly but significantly downregulated after iv-SIL,
suggesting impaired ability of pDC to stimulate T cells
and immune reactivity to the same extent as baseline
pDC. Moreover, CD86 expression (a maturation marker
which was not modified significantly by iv-SIL) on circu-
lating pDC was positively correlated with total bilirubin
level at baseline.
HLA-G and its receptor ILT4 are believed to play an
important role in regulating both the maturation and
function of DC. Thus, interaction between HLA-G and
its receptors inhibits DC maturation [30]. Moreover, sol-
uble HLA-G inhibits human DC-triggered allogeneic T
cell proliferation [31] and HLA-G-expressing antigen-
presenting cells induce CD4+ T cell Treg [32]. Although
not directly demonstrated in the present study, these
findings suggest that elevated HLA-G and ILT4 on per-
ipheral blood pDC may be consistent with the ability of
Table 3 Modulation of costimulatory and coregulatory molecule expression by iv-SIL
MFI (mean ± SD) pDC mDC
Pre Post p Pre Post p
HLA-DR 1673.5 ± 525.4 1523.4 ± 531.1 0.0092 2867.8 ± 440.9 2661.0 ± 573.2 0.1507
CD83 548.5 ± 187.7 755.0 ± 683.6 0.3982 374.9 ± 108.1 620.7 ± 392.5 0.0865
CD86 714.7 ± 174.0 743.6 ± 139.0 0.6359 1462.2 ± 322.8 1303.2 ± 328.0 0.4298
ICOSL 554.1 ± 223.8 640.4 ± 209.8 0.5265 498.2 ± 257.8 501.2 ± 133.7 0.9219
PD-L1 316.1 ± 110.7 376.8 ± 111.7 0.1848 272.0 ± 68.9 326.1 ± 88.6 0.1311
HLA-G 356.7 ± 57.8 409.9 ± 62.3 0.0583 567.7 ± 120.5 587.5 ± 108.4 0.6944
IL-T4 2303.6 ± 632.8 2743.4 ± 718.6 0.0165 1797.7 ± 424.0 2294.4 ± 570.7 0.0669
CD39 349.7 ± 116.9 437.8 ± 143.6 0.0456 1516.8 ± 269.2 1761.7 ± 527.6 0.2601
PD-L1/CD86 0.447 ± 0.110 0.5217 ± 0.197 0.3830 0.189 ± 0.042 0.268 ± 0.116 0.0929
PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86,
ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (MFI, mean SD) as well as the PD-L1/CD86 ratio on mDC and pDC is reported. Italicized values denote significance
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iv-SIL to promote a tolerogenic state. Moreover, expres-
sion of HLA-G on pDC after iv-SIL positively correlated
with total bilirubin level.
We also observed for the first time that after iv-SIL,
pDC, but not conventional mDC, exhibited significantly
higher levels of CD39 (% and MFI) than at baseline,
which was inversely correlated with viral load. It has
been shown that maturation of DC, an important con-
trol point in the development of immune responses, can
also be modulated by extracellular adenosine triphos-
phate (ATP) released by DC and also by damaged/nec-
rotic cells. CD39 is an ectoenzyme that degrades ATP to
AMP and can therefore modulate DC activation and in-
hibit their capacity to initiate Th1 responses [33]. In the
liver transplant setting, it may temper alloimmunity and
reduce the risk of graft injury and rejection [34].
The ICOS-ICOSL signaling pathway is involved in Th2
immune response enhancement and in germinal center
formation, somatic hypermutation, and class switch re-
combination [35–37]. Moreover, Treg are thought to
develop as a consequence of signaling through
costimulatory molecules [38], and some subsets of Treg
appear to depend on ICOS-ICOSL signaling pathway for
in vivo and in vitro suppression through IL-10 production
[39, 40]. Enhanced ICOSL expression by DC has also been
shown to be involved in the pathogenesis of infectious dis-
ease [41]. The present study demonstrates upregulation of
ICOSL on peripheral blood mDC after iv-SIL which was
inversely correlated with viral load. Several markers
(HLA-DR, PD-L1, and PD-L1/CD86 ratio) on mDC that
were not modified by iv-SIL treatment were positively cor-
related with transaminase levels.
Fig. 3 Modulation of costimulatory and coregulatory molecules by iv-SIL. PBMC were analyzed before (pre) and after (post) iv-SIL treatment by
flow cytometry, as described in the “Methods” section. Overall analyses of significantly modified markers on mDC (a ICOSL) and pDC (b HLA-DR
MFI, c HLA-G %, d ILT4 MFI, e CD39 %, and f CD39 MFI) are shown
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There is evidence that circulating levels of Treg are
elevated in tolerant liver transplant patients compared
with non-tolerant patients, or healthy individuals [12,
16, 42, 43]. Moreover, the expression of PD-1 on total
Treg as well as Treg subsets (naїve/central memory/ef-
fector memory/effector) is significantly higher in HCV-
infected patients than in healthy controls. In addition,
PD-1/PD-L1 signaling negatively regulates Treg by limit-
ing STAT-5 phosphorylation in patients with chronic
HCV infection, and PD-1 overexpression at the site of
inflammation is involved in the establishment of a long-
lasting inflammatory disease. The present study does not
show any significant change in the incidence of periph-
eral blood Treg or Foxp3 expression in liver transplant
patients after iv-SIL. Moreover, no change was also
found in PD-1 expression by Treg. These findings sug-
gest that despite a significant decrease in viral load by
the end of treatment [2], iv-SIL does not affect a possible
mechanism (PD-1/PD-L1 signaling on Treg cells) in-
volved in the persistence of HCV infection. This is con-
sistent with clinical findings showing that 16 days after
the end of the treatment, the infection persisted with
viral load mean values similar to baseline [2]. Interest-
ingly, although not modified by iv-SIL, the expression of
PD-L1 on Treg after treatment correlated positively with
HCV viral load and serum AST.
Correlations observed in the present study between
DC and Treg markers and liver functional tests, includ-
ing HCV viral load, have not been described previously,
and their biological/clinical significance is unclear. Thus,
Fig. 4 Correlation analyses between DC markers and clinical parameters. AST, ALT, total bilirubin, HCV RNA, HCV genotype, and IL-28B genotype
were analyzed in order to verify possible correlations with circulating DC subsets markers before (Fig. 4a–c) and after iv-SIL treatment (Fig. 4d–g).
DC markers at baseline were also correlated with clinical parameters at the end of iv-SIL treatment (Fig. 4h–i)
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larger prospective studies are needed to validate their
clinical significance. In order to discriminate the specific
roles of iv-SIL, HCV viral load and patient immune sup-
pression in affecting circulating DC and Treg, functional
and mechanistic in vitro studies need to be undertaken.
Conclusions
In conclusion, we believe that this is the first study in
liver transplant patients with HCV recurrence showing
the impact of iv-SIL on circulating DC and Treg. The
findings described reveal changes in circulating DC sub-
sets that have been associated previously with regula-
tory/tolerogenic conditions and suggest how Silibinin
might regulate alloimmunity and the anti-viral immune
response. Moreover, we have observed multiple clinical
correlations that could eventually improve the clinical
management of liver transplant patients and that deserve
further analysis.
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